Blog

Clinical research is complex. Sponsors cannot control every variable in a clinical trial. Recruitment challenges.Patient adherence.Biologic variability.Unexpected safety signals. These are inherent realities of drug development. But there is one risk that can be controlled: Duplicate research subjects entering clinical trials. And yet, across the industry, this issue continues to compromise patient safety, study integrity,

Clinical trial protocols routinely state that subjects must be:Clinical trial protocols frequently require that subjects be naïve to the investigational product. That requirement was not placed there casually. It exists for two fundamental reasons: 1. Patient safety2. Study integrity If prior exposure to the compound can alter safety signals, PK/PD behavior, dose response, or endpoint

Clinical research has long tolerated a quiet but persistent risk: duplicate subjects in clinical trials, professional research subjects, and dual enrollment in clinical trials.For years, these issues were viewed as operational nuisances—manageable, unfortunate, but expected. Sponsors adjusted. Sites absorbed the burden. CROs implemented workarounds. But at what point does “manageable” become materially dangerous? At what

Duplicate subjects in clinical trials and professional research subjects do not operate in isolation. They move across studies, sponsors, CROs, therapeutic areas, and geographies—often undetected when safeguards are fragmented or limited to individual sites. This is precisely why point solutions fail and why a networked research subject database becomes exponentially more powerful as adoption grows.

Verified Clinical Trials (VCT) will be attending SCOPE Summit 2026, where leaders from across the industry convene to advance the future of Clinical Trials. At SCOPE, our team will be reconnecting with many of our long-standing clients, colleagues, and friends, while also meeting new sponsors, CROs, and research partners. These conversations are essential as the